Subject-by-Formulation interaction? [Study As­sess­ment]

posted by Helmut Homepage – Vienna, Austria, 2020-07-22 14:03 (926 d 05:48 ago) – Posting: # 21775
Views: 1,818

Hi Loky do,

❝ Now another case for a non highly variable drug, […]



What you confirmed already:What is still possible:

❝ Is it applicable to consider these subjects as outliers, is there any way to conclude this?


That’s similar to the cases we discussed before. Even if you would perform a statistical test (which is not acceptable acc. to current regulatory practice), you would get a p-value of 0.2453 which would speak against excluding them. Even for Health Canada (where an outlier assessment of studentized model residuals can be done if pre-specified in the protocol) you could exclude only one subject (≤5% if the sample size is ≥20).

❝ or could we re-dose them again to be confirmed?


Re-dosing is discouraged and likely not accepted.

❝ or simply the product fails :-|?


I’m afraid, yes.

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
22,478 posts in 4,708 threads, 1,604 registered users;
16 visitors (0 registered, 16 guests [including 8 identified bots]).
Forum time: 18:51 CET (Europe/Vienna)

Learning of many things
does not teach intelligence.    Heraclitus of Ephesus

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5